GET DAILY SIGNALSIronwood Pharmaceuticals (IRWD) Delivers Q3 2026 Revenue Growth of 9% and Raises Guidance Again
Key Takeaways
- Ironwood Pharmaceuticals reported third-quarter 2026 total revenue of $133.0 million, up roughly 9% from $122.1 million in the same period a year earlier.
- GAAP diluted earnings per share came in at $0.36, exceeding consensus estimates, while adjusted EBITDA reached a record $97.9 million.
- LINZESS U.S. net sales rose 3.2% to $324.9 million, with total prescription demand up 4.9% year over year.
- Management raised full-year 2026 guidance for the second time this year, now projecting LINZESS U.S. net sales of $1.20–$1.25 billion and adjusted EBITDA of more than $350 million.
- Ironwood repaid $60.0 million of its revolving credit facility, reducing the outstanding balance to $325.0 million and strengthening the balance sheet.
Earnings Context and Why It Matters
Ironwood Pharmaceuticals' quarterly earnings draw close attention because the company's performance hinges almost entirely on one product: LINZESS, a treatment for irritable bowel syndrome with constipation and chronic idiopathic constipation, marketed in partnership with AbbVie. The company records its share of U.S. LINZESS profits as collaboration revenue, so the brand's net sales, prescription trends, and margins drive nearly all of its financial results. Following the January 2025 restructuring and efforts to strengthen the balance sheet, investors have been monitoring whether better net pricing and consistent demand can support ongoing profitability. This quarter provides a useful test of that outlook, especially with a notable Medicare Part D pricing shift scheduled for 2027.
Breaking Down the Reported Results
Ironwood Pharmaceuticals reported third-quarter 2026 total revenue of $133.0 million, an increase from $122.1 million in the third quarter of 2025. GAAP net income reached $59.8 million, or $0.36 per diluted share, compared with $40.1 million, or $0.23 per diluted share, in the prior-year period. Adjusted EBITDA rose to a record $97.9 million, up from $81.8 million a year earlier. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
At the brand level, LINZESS U.S. net sales, as reported by partner AbbVie, totaled $324.9 million in the quarter, a 3.2% increase from $314.9 million a year ago. Total prescription demand grew 4.9% year over year, according to IQVIA data. Year-to-date U.S. net sales reached roughly $879.8 million through September 30, 2026, already exceeding the full-year 2025 total.
Management raised its full-year 2026 outlook for the second straight quarter. The company now expects LINZESS U.S. net sales of $1.20–$1.25 billion (up from $1.15–$1.20 billion), total revenue of $485–$510 million (up from $460–$485 million), and adjusted EBITDA of more than $350 million (up from more than $310 million).
Market Reaction and Investor Sentiment
The market response to Ironwood's third-quarter report showed a blend of appreciation for profit strength and questions around top-line growth. The earnings-per-share beat and the second guidance increase of the year stood out as positives, highlighting improved profitability in the LINZESS franchise. At the same time, focus shifted to the brand's sales trajectory, where year-over-year growth slowed to low single digits even as margins expanded. Sentiment reflects two main themes: solid near-term cash flow and margin gains on one hand, and the upcoming Medicare Part D maximum fair price change on the other, which management has noted could limit pricing benefits starting in 2027.
Forward Outlook and Key Factors to Monitor
Looking ahead, several elements tied to the LINZESS franchise and the broader pipeline warrant attention. Management expects the fourth quarter of 2026 to be the strongest of the year, backed by mid-single-digit prescription demand growth. Whether that pace continues into 2027 remains an open question, given the Medicare Part D maximum fair price of $136 per month that begins January 1, 2027. The company has not yet issued 2027 guidance and has indicated that additional pricing support may be limited in the 2027–2028 period.
The balance sheet continues to draw focus. Ironwood repaid $60 million of its revolving credit facility in the quarter and is targeting less than $300 million in gross debt and leverage below 1x by year-end, with management signaling a possible move toward returning capital to shareholders. Capital allocation choices will therefore stay in view.
The clinical pipeline is also gaining relevance. The STARS-2 confirmatory Phase 3 trial of apraglutide remains in enrollment, with primary completion expected in October 2028 and a potential NDA filing in 2029. Leadership changes, including a CEO transition planned for January 1 and an interim CFO in place, represent another area for investors to follow.
Exploring AI Tools for Stock Analysis
In my research process, I often turn to Tickeron's AI Screener to quickly filter healthcare stocks by fundamentals, technical patterns, and performance metrics. It helps surface comparable ideas without manual effort and supports a more structured review of names like IRWD alongside peers. This tool has become a regular part of how I evaluate earnings reports and sector trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IRWD sees its Stochastic Oscillator ascending out of oversold territory
On October 28, 2026, the Stochastic Oscillator for IRWD moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 52 instances where the indicator left the oversold zone. In 42 of the 52 cases the stock moved higher in the following days. This puts the odds of a move higher at over 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IRWD's RSI Oscillator exited the oversold zone, 26 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on IRWD as a result. In 71 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for IRWD just turned positive on October 28, 2026. Looking at past instances where IRWD's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
Following a +8.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRWD advanced for three days, in 180 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The 10-day moving average for IRWD crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
The 50-day moving average for IRWD moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRWD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
IRWD broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IRWD entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.849) is normal, around the industry mean (7.659). P/E Ratio (4.713) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.780) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. IRWD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRWD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of innovative human medicines
Industry PharmaceuticalsGeneric
Advertisement